#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-7	Altered	_
1-2	8-15	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
1-3	16-21	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
1-4	22-32	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
1-5	33-45	connectivity	_
1-6	46-48	in	_
1-7	49-54	early	_
1-8	55-61	course	_
1-9	62-75	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-10	76-84	Impaired	_
1-11	85-97	connectivity	_
1-12	98-100	is	_
1-13	101-109	proposed	_
1-14	110-112	to	_
1-15	113-121	underlie	_
1-16	122-137	pathophysiology	_
1-17	138-140	of	_
1-18	141-154	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-19	155-156	.	_

2-1	157-165	Existing	_
2-2	166-173	studies	_
2-3	174-176	on	_
2-4	177-187	functional	_
2-5	188-200	connectivity	_
2-6	201-205	show	_
2-7	206-218	inconsistent	_
2-8	219-226	results	_
2-9	227-228	.	_

3-1	229-231	We	_
3-2	232-240	examined	_
3-3	241-251	functional	_
3-4	252-264	connectivity	_
3-5	265-267	in	_
3-6	268-269	a	_
3-7	270-280	clinically	_
3-8	281-291	homogenous	_
3-9	292-298	sample	_
3-10	299-301	of	_
3-11	302-304	34	_
3-12	305-310	early	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-13	311-317	course	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-14	318-331	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-15	332-340	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-16	341-349	compared	_
3-17	350-357	with/to	_
3-18	358-360	19	_
3-19	361-368	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-20	369-377	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-21	378-383	using	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-22	384-391	resting	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-23	392-397	state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-24	398-408	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-25	409-417	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-26	418-427	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-27	428-435	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-28	436-437	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-29	438-444	rsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-30	445-446	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-31	447-448	.	_

4-1	449-453	Mean	_
4-2	454-462	duration	_
4-3	463-465	of	_
4-4	466-473	illness	_
4-5	474-477	for	_
4-6	478-491	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-7	492-500	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-8	501-504	was	_
4-9	505-506	4	_
4-10	507-508	±	_
4-11	509-513	1.78	_
4-12	514-519	years	_
4-13	520-521	.	_

5-1	522-531	Following	_
5-2	532-533	a	_
5-3	534-547	comprehensive	_
5-4	548-556	clinical	_
5-5	557-567	assessment	_
5-6	568-569	,	_
5-7	570-576	rsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#Thing
5-8	577-581	data	_
5-9	582-586	were	_
5-10	587-595	acquired	_
5-11	596-601	using	_
5-12	602-603	a	_
5-13	604-607	3.0	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
5-14	608-609	T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
5-15	610-618	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
5-16	619-628	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
5-17	629-636	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
5-18	637-644	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
5-19	645-646	,	_
5-20	647-650	and	_
5-21	651-659	analyzed	_
5-22	660-665	using	_
5-23	666-669	FSL	_
5-24	670-677	version	_
5-25	678-682	5.01	_
5-26	683-691	software	_
5-27	692-693	(	_
5-28	694-699	FMRIB	_
5-29	700-701	’	_
5-30	702-703	s	_
5-31	704-712	Software	_
5-32	713-720	Library	_
5-33	721-722	,	_
5-34	723-745	www.fmrib.ox.ac.uk/fsl	_
5-35	746-747	)	_
5-36	748-749	.	_

6-1	750-758	Compared	_
6-2	759-761	to	_
6-3	762-769	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-4	770-778	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-5	779-780	,	_
6-6	781-794	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-7	795-803	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-8	804-807	had	_
6-9	808-821	significantly	_
6-10	822-831	decreased	_
6-11	832-842	functional	_
6-12	843-855	connectivity	_
6-13	856-858	in	_
6-14	859-862	the	_
6-15	863-867	left	_
6-16	868-883	fronto-parietal	_
6-17	884-891	network	_
6-18	892-893	,	_
6-19	894-901	lateral	_
6-20	902-905	and	_
6-21	906-912	medial	_
6-22	913-919	visual	_
6-23	920-927	network	_
6-24	928-929	,	_
6-25	930-935	motor	_
6-26	936-943	network	_
6-27	944-945	,	_
6-28	946-953	default	_
6-29	954-958	mode	_
6-30	959-966	network	_
6-31	967-970	and	_
6-32	971-979	auditory	_
6-33	980-987	network	_
6-34	988-989	.	_

7-1	990-993	Our	_
7-2	994-998	data	_
7-3	999-1007	suggests	_
7-4	1008-1019	significant	_
7-5	1020-1030	functional	_
7-6	1031-1047	hypoconnectivity	_
7-7	1048-1050	in	_
7-8	1051-1059	selected	_
7-9	1060-1065	brain	_
7-10	1066-1074	networks	_
7-11	1075-1077	in	_
7-12	1078-1083	early	_
7-13	1084-1097	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-14	1098-1106	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-15	1107-1115	compared	_
7-16	1116-1118	to	_
7-17	1119-1127	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-18	1128-1129	.	_

8-1	1130-1132	It	_
8-2	1133-1135	is	_
8-3	1136-1142	likely	_
8-4	1143-1147	that	_
8-5	1148-1151	the	_
8-6	1152-1160	observed	_
8-7	1161-1171	functional	_
8-8	1172-1188	hypoconnectivity	_
8-9	1189-1192	may	_
8-10	1193-1195	be	_
8-11	1196-1206	associated	_
8-12	1207-1211	with	_
8-13	1212-1220	features	_
8-14	1221-1223	of	_
8-15	1224-1237	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-16	1238-1243	other	_
8-17	1244-1248	than	_
8-18	1249-1254	those	_
8-19	1255-1263	examined	_
8-20	1264-1266	in	_
8-21	1267-1271	this	_
8-22	1272-1277	study	_
8-23	1278-1279	.	_

9-1	1280-1282	It	_
9-2	1283-1285	is	_
9-3	1286-1294	possible	_
9-4	1295-1299	that	_
9-5	1300-1316	hypoconnectivity	_
9-6	1317-1319	is	_
9-7	1320-1329	necessary	_
9-8	1330-1333	but	_
9-9	1334-1337	not	_
9-10	1338-1348	sufficient	_
9-11	1349-1351	to	_
9-12	1352-1355	the	_
9-13	1356-1364	clinical	_
9-14	1365-1378	manifestation	_
9-15	1379-1381	of	_
9-16	1382-1395	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-17	1396-1397	.	_

10-1	1398-1401	The	_
10-2	1402-1413	examination	_
10-3	1414-1416	of	_
10-4	1417-1427	functional	_
10-5	1428-1440	connectivity	_
10-6	1441-1443	as	_
10-7	1444-1445	a	_
10-8	1446-1455	biomarker	_
10-9	1456-1462	should	_
10-10	1463-1465	be	_
10-11	1466-1474	extended	_
10-12	1475-1477	to	_
10-13	1478-1479	a	_
10-14	1480-1485	wider	_
10-15	1486-1491	array	_
10-16	1492-1494	of	_
10-17	1495-1502	disease	_
10-18	1503-1513	phenotypes	_
10-19	1514-1516	to	_
10-20	1517-1523	better	_
10-21	1524-1534	understand	_
10-22	1535-1538	its	_
10-23	1539-1551	significance	_
10-24	1552-1553	.	_

11-1	1554-1555	2	_
11-2	1556-1557	.	_

12-1	1558-1565	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-2	1566-1569	2.1	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-3	1570-1571	.	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod

13-1	1572-1580	Clinical	_
13-2	1581-1592	assessments	_
13-3	1593-1600	Persons	_
13-4	1601-1605	with	_
13-5	1606-1611	early	_
13-6	1612-1618	course	_
13-7	1619-1632	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-8	1633-1640	seeking	_
13-9	1641-1650	treatment	_
13-10	1651-1653	at	_
13-11	1654-1657	the	_
13-12	1658-1668	Department	_
13-13	1669-1671	of	_
13-14	1672-1682	Psychiatry	_
13-15	1683-1684	,	_
13-16	1685-1688	Dr.	_
13-17	1689-1692	Ram	_
13-18	1693-1700	Manohar	_
13-19	1701-1706	Lohia	_
13-20	1707-1715	Hospital	_
13-21	1716-1717	,	_
13-22	1718-1721	New	_
13-23	1722-1727	Delhi	_
13-24	1728-1729	,	_
13-25	1730-1735	India	_
13-26	1736-1740	were	_
13-27	1741-1749	enrolled	_
13-28	1750-1757	through	_
13-29	1758-1763	their	_
13-30	1764-1772	treating	_
13-31	1773-1783	clinicians	_
13-32	1784-1785	.	_

14-1	1786-1794	Eligible	_
14-2	1795-1803	subjects	_
14-3	1804-1808	with	_
14-4	1809-1814	early	_
14-5	1815-1821	course	_
14-6	1822-1835	schizophrenia	_
14-7	1836-1838	of	_
14-8	1839-1843	both	_
14-9	1844-1849	sexes	_
14-10	1850-1857	between	_
14-11	1858-1860	18	_
14-12	1861-1864	and	_
14-13	1865-1867	50	_
14-14	1868-1873	years	_
14-15	1874-1875	,	_
14-16	1876-1879	and	_
14-17	1880-1888	controls	_
14-18	1889-1893	were	_
14-19	1894-1903	explained	_
14-20	1904-1909	about	_
14-21	1910-1913	all	_
14-22	1914-1919	study	_
14-23	1920-1930	procedures	_
14-24	1931-1934	and	_
14-25	1935-1942	written	_
14-26	1943-1951	informed	_
14-27	1952-1959	consent	_
14-28	1960-1963	was	_
14-29	1964-1972	obtained	_
14-30	1973-1974	.	_

15-1	1975-1983	Controls	_
15-2	1984-1988	were	_
15-3	1989-1997	selected	_
15-4	1998-2000	to	_
15-5	2001-2006	match	_
15-6	2007-2010	age	_
15-7	2011-2014	and	_
15-8	2015-2018	sex	_
15-9	2019-2020	(	_
15-10	2021-2032	highlighted	_
15-11	2033-2035	in	_
15-12	2036-2043	results	_
15-13	2044-2045	)	_
15-14	2046-2047	.	_

16-1	2048-2051	The	_
16-2	2052-2061	diagnosis	_
16-3	2062-2065	was	_
16-4	2066-2075	confirmed	_
16-5	2076-2078	by	_
16-6	2079-2092	administering	_
16-7	2093-2094	a	_
16-8	2095-2105	structured	_
16-9	2106-2115	interview	_
16-10	2116-2121	using	_
16-11	2122-2125	the	_
16-12	2126-2131	Hindi	_
16-13	2132-2139	version	_
16-14	2140-2142	of	_
16-15	2143-2146	the	_
16-16	2147-2157	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
16-17	2158-2167	Interview	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
16-18	2168-2171	for	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
16-19	2172-2179	Genetic	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
16-20	2180-2187	Studies	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
16-21	2188-2189	(	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
16-22	2190-2194	DIGS	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
16-23	2195-2196	)	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
16-24	2197-2198	,	_
16-25	2199-2204	which	_
16-26	2205-2208	has	_
16-27	2209-2213	been	_
16-28	2214-2223	validated	_
16-29	2224-2234	previously	_
16-30	2235-2236	.	_

17-1	2237-2240	The	_
17-2	2241-2245	DIGS	_
17-3	2246-2254	includes	_
17-4	2255-2258	the	_
17-5	2259-2265	Global	http://maven.renci.org/NeuroBridge/neurobridge#MentalStateAssessmentScale
17-6	2266-2276	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#MentalStateAssessmentScale
17-7	2277-2282	Scale	http://maven.renci.org/NeuroBridge/neurobridge#MentalStateAssessmentScale
17-8	2283-2284	(	http://maven.renci.org/NeuroBridge/neurobridge#MentalStateAssessmentScale
17-9	2285-2288	GAS	http://maven.renci.org/NeuroBridge/neurobridge#MentalStateAssessmentScale
17-10	2289-2290	)	http://maven.renci.org/NeuroBridge/neurobridge#MentalStateAssessmentScale
17-11	2291-2292	,	_
17-12	2293-2296	the	_
17-13	2297-2305	Schedule	_
17-14	2306-2309	for	_
17-15	2310-2320	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
17-16	2321-2323	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
17-17	2324-2332	Positive	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
17-18	2333-2341	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
17-19	2342-2343	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
17-20	2344-2348	SAPS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
17-21	2349-2350	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
17-22	2351-2352	,	_
17-23	2353-2356	and	_
17-24	2357-2360	the	_
17-25	2361-2369	Schedule	_
17-26	2370-2373	for	_
17-27	2374-2384	Assessment	_
17-28	2385-2387	of	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
17-29	2388-2396	Negative	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
17-30	2397-2405	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
17-31	2406-2407	(	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
17-32	2408-2412	SANS	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
17-33	2413-2414	)	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
17-34	2415-2416	.	_

18-1	2417-2420	The	_
18-2	2421-2425	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
18-3	2426-2429	and	_
18-4	2430-2434	SAPS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
18-5	2435-2441	assess	_
18-6	2442-2445	the	_
18-7	2446-2454	severity	_
18-8	2455-2457	of	_
18-9	2458-2466	negative	_
18-10	2467-2470	and	_
18-11	2471-2479	positive	_
18-12	2480-2488	symptoms	_
18-13	2489-2491	on	_
18-14	2492-2493	a	_
18-15	2494-2503	six-point	_
18-16	2504-2509	scale	_
18-17	2510-2512	in	_
18-18	2513-2516	the	_
18-19	2517-2525	previous	_
18-20	2526-2531	month	_
18-21	2532-2533	.	_

19-1	2534-2545	Inter-rater	_
19-2	2546-2557	reliability	_
19-3	2558-2560	of	_
19-4	2561-2568	scoring	_
19-5	2569-2572	was	_
19-6	2573-2582	0.83–0.92	_
19-7	2583-2584	.	_

20-1	2585-2587	In	_
20-2	2588-2596	addition	_
20-3	2597-2599	to	_
20-4	2600-2610	structured	_
20-5	2611-2618	patient	_
20-6	2619-2628	interview	_
20-7	2629-2630	,	_
20-8	2631-2641	collateral	_
20-9	2642-2653	information	_
20-10	2654-2657	was	_
20-11	2658-2666	obtained	_
20-12	2667-2674	through	_
20-13	2675-2685	caregivers	_
20-14	2686-2687	.	_

21-1	2688-2690	We	_
21-2	2691-2698	defined	_
21-3	2699-2704	early	_
21-4	2705-2711	course	_
21-5	2712-2725	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
21-6	2726-2728	as	_
21-7	2729-2732	the	_
21-8	2733-2740	illness	_
21-9	2741-2749	duration	_
21-10	2750-2752	of	_
21-11	2753-2754	7	_
21-12	2755-2760	years	_
21-13	2761-2763	or	_
21-14	2764-2768	less	_
21-15	2769-2773	from	_
21-16	2774-2777	the	_
21-17	2778-2783	onset	_
21-18	2784-2786	of	_
21-19	2787-2792	first	_
21-20	2793-2802	psychotic	_
21-21	2803-2811	symptoms	_
21-22	2812-2813	.	_

22-1	2814-2817	The	_
22-2	2818-2826	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
22-3	2827-2830	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
22-4	2831-2839	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
22-5	2840-2848	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
22-6	2849-2854	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
22-7	2855-2856	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
22-8	2857-2862	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
22-9	2863-2864	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
22-10	2865-2868	was	_
22-11	2869-2881	administered	_
22-12	2882-2884	to	_
22-13	2885-2889	rate	_
22-14	2890-2893	the	_
22-15	2894-2902	presence	_
22-16	2903-2906	and	_
22-17	2907-2915	severity	_
22-18	2916-2918	of	_
22-19	2919-2928	psychotic	_
22-20	2929-2937	symptoms	_
22-21	2938-2939	.	_

23-1	2940-2952	Participants	_
23-2	2953-2957	were	_
23-3	2958-2966	required	_
23-4	2967-2969	to	_
23-5	2970-2974	have	_
23-6	2975-2976	a	_
23-7	2977-2982	score	_
23-8	2983-2985	of	_
23-9	2986-2987	4	_
23-10	2988-2990	or	_
23-11	2991-2995	more	_
23-12	2996-2998	on	_
23-13	2999-3002	one	_
23-14	3003-3005	or	_
23-15	3006-3010	more	_
23-16	3011-3016	items	_
23-17	3017-3019	of	_
23-18	3020-3023	the	_
23-19	3024-3029	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-20	3030-3031	,	_
23-21	3032-3035	and	_
23-22	3036-3038	be	_
23-23	3039-3041	on	_
23-24	3042-3043	a	_
23-25	3044-3050	stable	_
23-26	3051-3055	dose	_
23-27	3056-3058	of	_
23-28	3059-3073	antipsychotics	_
23-29	3074-3077	for	_
23-30	3078-3080	at	_
23-31	3081-3086	least	_
23-32	3087-3088	1	_
23-33	3089-3094	month	_
23-34	3095-3100	prior	_
23-35	3101-3103	to	_
23-36	3104-3116	experimental	_
23-37	3117-3127	procedures	_
23-38	3128-3129	.	_

24-1	3130-3133	For	_
24-2	3134-3137	the	_
24-3	3138-3145	control	_
24-4	3146-3151	group	_
24-5	3152-3153	,	_
24-6	3154-3164	comparable	_
24-7	3165-3177	participants	_
24-8	3178-3181	not	_
24-9	3182-3191	suffering	_
24-10	3192-3196	from	_
24-11	3197-3200	any	_
24-12	3201-3212	psychiatric	_
24-13	3213-3220	illness	_
24-14	3221-3225	were	_
24-15	3226-3234	enrolled	_
24-16	3235-3239	from	_
24-17	3240-3247	similar	_
24-18	3248-3261	neighborhoods	_
24-19	3262-3263	.	_

25-1	3264-3276	Participants	_
25-2	3277-3281	with	_
25-3	3282-3283	a	_
25-4	3284-3291	history	_
25-5	3292-3294	of	_
25-6	3295-3304	substance	_
25-7	3305-3315	dependence	_
25-8	3316-3318	in	_
25-9	3319-3322	the	_
25-10	3323-3327	past	_
25-11	3328-3329	6	_
25-12	3330-3336	months	_
25-13	3337-3338	,	_
25-14	3339-3348	excluding	_
25-15	3349-3357	nicotine	_
25-16	3358-3368	dependence	_
25-17	3369-3370	,	_
25-18	3371-3376	those	_
25-19	3377-3381	with	_
25-20	3382-3383	a	_
25-21	3384-3391	history	_
25-22	3392-3394	of	_
25-23	3395-3397	or	_
25-24	3398-3405	current	_
25-25	3406-3426	medical/neurological	_
25-26	3427-3436	illnesses	_
25-27	3437-3438	,	_
25-28	3439-3442	e.g	_
25-29	3443-3444	.	_

26-1	3445-3453	epilepsy	_
26-2	3454-3458	were	_
26-3	3459-3467	excluded	_
26-4	3468-3469	.	_

27-1	3470-3479	Pregnancy	_
27-2	3480-3481	,	_
27-3	3482-3488	mental	_
27-4	3489-3500	retardation	_
27-5	3501-3502	(	_
27-6	3503-3509	DSM-IV	_
27-7	3510-3511	)	_
27-8	3512-3514	or	_
27-9	3515-3518	any	_
27-10	3519-3535	contraindication	_
27-11	3536-3538	to	_
27-12	3539-3542	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
27-13	3543-3553	procedures	_
27-14	3554-3555	,	_
27-15	3556-3560	such	_
27-16	3561-3563	as	_
27-17	3564-3570	having	_
27-18	3571-3581	pacemakers	_
27-19	3582-3584	or	_
27-20	3585-3590	metal	_
27-21	3591-3609	fragments/shrapnel	_
27-22	3610-3614	were	_
27-23	3615-3618	the	_
27-24	3619-3624	other	_
27-25	3625-3634	exclusion	_
27-26	3635-3643	criteria	_
27-27	3644-3645	.	_

28-1	3646-3649	2.2	_
28-2	3650-3651	.	_

29-1	3652-3659	Imaging	_
29-2	3660-3667	methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
29-3	3668-3673	Brain	_
29-4	3674-3680	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
29-5	3681-3685	were	_
29-6	3686-3694	acquired	_
29-7	3695-3700	using	_
29-8	3701-3702	a	_
29-9	3703-3704	3	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
29-10	3705-3706	T	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
29-11	3707-3717	whole-body	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
29-12	3718-3721	MRI	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
29-13	3722-3729	scanner	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
29-14	3730-3731	(	_
29-15	3732-3740	Magnetom	_
29-16	3741-3746	Skyra	_
29-17	3747-3748	,	_
29-18	3749-3756	Siemens	_
29-19	3757-3758	)	_
29-20	3759-3764	while	_
29-21	3765-3777	participants	_
29-22	3778-3781	lay	_
29-23	3782-3788	supine	_
29-24	3789-3790	.	_

30-1	3791-3795	Foam	_
30-2	3796-3800	pads	_
30-3	3801-3803	on	_
30-4	3804-3810	either	_
30-5	3811-3815	side	_
30-6	3816-3818	of	_
30-7	3819-3822	the	_
30-8	3823-3827	head	_
30-9	3828-3832	were	_
30-10	3833-3837	used	_
30-11	3838-3840	to	_
30-12	3841-3849	minimize	_
30-13	3850-3854	head	_
30-14	3855-3863	movement	_
30-15	3864-3865	.	_

31-1	3866-3878	Participants	_
31-2	3879-3883	were	_
31-3	3884-3894	instructed	_
31-4	3895-3898	not	_
31-5	3899-3901	to	_
31-6	3902-3906	move	_
31-7	3907-3908	,	_
31-8	3909-3912	and	_
31-9	3913-3915	to	_
31-10	3916-3919	lie	_
31-11	3920-3927	quietly	_
31-12	3928-3933	awake	_
31-13	3934-3935	,	_
31-14	3936-3940	with	_
31-15	3941-3947	closed	_
31-16	3948-3952	eyes	_
31-17	3953-3956	and	_
31-18	3957-3960	not	_
31-19	3961-3968	engaged	_
31-20	3969-3971	in	_
31-21	3972-3975	any	_
31-22	3976-3984	specific	_
31-23	3985-3994	cognitive	_
31-24	3995-4003	activity	_
31-25	4004-4010	during	_
31-26	4011-4014	the	_
31-27	4015-4025	experiment	_
31-28	4026-4027	.	_

32-1	4028-4030	We	_
32-2	4031-4040	collected	_
32-3	4041-4056	high-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
32-4	4057-4068	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
32-5	4069-4075	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
32-6	4076-4081	using	_
32-7	4082-4083	a	_
32-8	4084-4097	magnetization	_
32-9	4098-4106	prepared	_
32-10	4107-4112	rapid	_
32-11	4113-4124	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodExperienceofCareandAbuseQuestionnaire
32-12	4125-4138	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodExperienceofCareandAbuseQuestionnaire
32-13	4139-4140	(	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodExperienceofCareandAbuseQuestionnaire
32-14	4141-4147	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodExperienceofCareandAbuseQuestionnaire
32-15	4148-4149	)	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodExperienceofCareandAbuseQuestionnaire
32-16	4150-4158	sequence	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodExperienceofCareandAbuseQuestionnaire
32-17	4159-4160	(	_
32-18	4161-4163	TR	_
32-19	4164-4165	=	_
32-20	4166-4170	1900	_
32-21	4171-4173	ms	_
32-22	4174-4175	;	_
32-23	4176-4178	TE	_
32-24	4179-4180	=	_
32-25	4181-4185	2.07	_
32-26	4186-4188	ms	_
32-27	4189-4190	;	_
32-28	4191-4200	inversion	_
32-29	4201-4205	time	_
32-30	4206-4207	=	_
32-31	4208-4211	900	_
32-32	4212-4214	ms	_
32-33	4215-4216	;	_
32-34	4217-4221	flip	_
32-35	4222-4227	angle	_
32-36	4228-4229	(	_
32-37	4230-4232	FA	_
32-38	4233-4234	)	_
32-39	4235-4236	=	_
32-40	4237-4239	9°	_
32-41	4240-4241	;	_
32-42	4242-4245	FOV	_
32-43	4246-4247	=	_
32-44	4248-4251	256	_
32-45	4252-4253	×	_
32-46	4254-4257	256	_
32-47	4258-4260	mm	_
32-48	4261-4262	;	_
32-49	4263-4268	slice	_
32-50	4269-4278	thickness	_
32-51	4279-4280	=	_
32-52	4281-4282	1	_
32-53	4283-4285	mm	_
32-54	4286-4287	;	_
32-55	4288-4294	number	_
32-56	4295-4297	of	_
32-57	4298-4304	slices	_
32-58	4305-4306	=	_
32-59	4307-4310	160	_
32-60	4311-4312	)	_
32-61	4313-4314	.	_

33-1	4315-4317	We	_
33-2	4318-4326	acquired	_
33-3	4327-4338	T2-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
33-4	4339-4345	images	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
33-5	4346-4347	[	_
33-6	4348-4358	repetition	_
33-7	4359-4363	time	_
33-8	4364-4365	(	_
33-9	4366-4368	TR	_
33-10	4369-4370	)	_
33-11	4371-4372	=	_
33-12	4373-4379	10,000	_
33-13	4380-4382	ms	_
33-14	4383-4384	;	_
33-15	4385-4387	TE	_
33-16	4388-4389	=	_
33-17	4390-4393	100	_
33-18	4394-4396	ms	_
33-19	4397-4398	;	_
33-20	4399-4401	FA	_
33-21	4402-4403	=	_
33-22	4404-4408	150°	_
33-23	4409-4410	]	_
33-24	4411-4416	using	_
33-25	4417-4418	a	_
33-26	4419-4428	dual-echo	_
33-27	4429-4434	turbo	_
33-28	4435-4444	spin-echo	_
33-29	4445-4453	sequence	_
33-30	4454-4456	in	_
33-31	4457-4460	the	_
33-32	4461-4466	axial	_
33-33	4467-4472	plane	_
33-34	4473-4474	,	_
33-35	4475-4479	with	_
33-36	4480-4481	a	_
33-37	4482-4485	256	_
33-38	4486-4487	×	_
33-39	4488-4491	256	_
33-40	4492-4498	matrix	_
33-41	4499-4503	size	_
33-42	4504-4505	,	_
33-43	4506-4513	220×220	_
33-44	4514-4516	mm	_
33-45	4517-4522	field	_
33-46	4523-4525	of	_
33-47	4526-4530	view	_
33-48	4531-4532	(	_
33-49	4533-4536	FOV	_
33-50	4537-4538	)	_
33-51	4539-4540	,	_
33-52	4541-4544	4.0	_
33-53	4545-4547	mm	_
33-54	4548-4553	slice	_
33-55	4554-4563	thickness	_
33-56	4564-4565	,	_
33-57	4566-4569	and	_
33-58	4570-4573	1.2	_
33-59	4574-4576	mm	_
33-60	4577-4587	interslice	_
33-61	4588-4591	gap	_
33-62	4592-4594	to	_
33-63	4595-4598	aid	_
33-64	4599-4601	in	_
33-65	4602-4612	anatomical	_
33-66	4613-4627	identification	_
33-67	4628-4631	and	_
33-68	4632-4642	evaluation	_
33-69	4643-4646	for	_
33-70	4647-4650	any	_
33-71	4651-4661	anatomical	_
33-72	4662-4669	defects	_
33-73	4670-4671	.	_

34-1	4672-4674	We	_
34-2	4675-4679	also	_
34-3	4680-4689	collected	_
34-4	4690-4700	functional	_
34-5	4701-4706	brain	_
34-6	4707-4714	volumes	_
34-7	4715-4720	using	_
34-8	4721-4723	an	_
34-9	4724-4735	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
34-10	4736-4738	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-11	4739-4740	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-12	4741-4750	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-13	4751-4758	imaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-14	4759-4767	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-15	4768-4769	.	_

35-1	4770-4774	Each	_
35-2	4775-4781	volume	_
35-3	4782-4791	consisted	_
35-4	4792-4794	of	_
35-5	4795-4797	30	_
35-6	4798-4809	interleaved	_
35-7	4810-4814	5-mm	_
35-8	4815-4820	thick	_
35-9	4821-4827	slices	_
35-10	4828-4835	without	_
35-11	4836-4846	interslice	_
35-12	4847-4850	gap	_
35-13	4851-4852	(	_
35-14	4853-4855	TE	_
35-15	4856-4857	=	_
35-16	4858-4860	30	_
35-17	4861-4863	ms	_
35-18	4864-4865	,	_
35-19	4866-4868	TR	_
35-20	4869-4870	=	_
35-21	4871-4875	2000	_
35-22	4876-4878	ms	_
35-23	4879-4880	,	_
35-24	4881-4884	FOV	_
35-25	4885-4886	=	_
35-26	4887-4890	240	_
35-27	4891-4893	mm	_
35-28	4894-4895	,	_
35-29	4896-4900	flip	_
35-30	4901-4906	angle	_
35-31	4907-4908	=	_
35-32	4909-4912	90°	_
35-33	4913-4914	,	_
35-34	4915-4920	voxel	_
35-35	4921-4925	size	_
35-36	4926-4927	=	_
35-37	4928-4932	3.75	_
35-38	4933-4934	×	_
35-39	4935-4939	3.75	_
35-40	4940-4941	×	_
35-41	4942-4943	5	_
35-42	4944-4947	mm3	_
35-43	4948-4949	)	_
35-44	4950-4951	.	_

36-1	4952-4957	Total	_
36-2	4958-4966	scanning	_
36-3	4967-4971	time	_
36-4	4972-4975	for	_
36-5	4976-4980	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
36-6	4981-4984	was	_
36-7	4985-4989	6.83	_
36-8	4990-4993	min	_
36-9	4994-4995	(	_
36-10	4996-4999	205	_
36-11	5000-5005	brain	_
36-12	5006-5013	volumes	_
36-13	5014-5015	)	_
36-14	5016-5017	.	_

37-1	5018-5024	Images	_
37-2	5025-5029	were	_
37-3	5030-5040	re-checked	_
37-4	5041-5044	for	_
37-5	5045-5052	quality	_
37-6	5053-5055	at	_
37-7	5056-5059	the	_
37-8	5060-5063	end	_
37-9	5064-5066	of	_
37-10	5067-5072	every	_
37-11	5073-5077	scan	_
37-12	5078-5079	,	_
37-13	5080-5083	and	_
37-14	5084-5086	if	_
37-15	5087-5090	any	_
37-16	5091-5095	head	_
37-17	5096-5104	movement	_
37-18	5105-5108	was	_
37-19	5109-5119	noticeable	_
37-20	5120-5121	,	_
37-21	5122-5125	the	_
37-22	5126-5130	scan	_
37-23	5131-5134	was	_
37-24	5135-5143	repeated	_
37-25	5144-5145	.	_

38-1	5146-5149	2.3	_
38-2	5150-5151	.	_

39-1	5152-5156	Plan	_
39-2	5157-5159	of	_
39-3	5160-5168	analysis	_
39-4	5169-5171	We	_
39-5	5172-5176	used	_
39-6	5177-5180	the	_
39-7	5181-5192	Statistical	_
39-8	5193-5200	Package	_
39-9	5201-5204	for	_
39-10	5205-5211	Social	_
39-11	5212-5220	Sciences	_
39-12	5221-5222	(	_
39-13	5223-5227	SPSS	_
39-14	5228-5231	v21	_
39-15	5232-5233	)	_
39-16	5234-5237	for	_
39-17	5238-5248	assessment	_
39-18	5249-5251	of	_
39-19	5252-5263	demographic	_
39-20	5264-5267	and	_
39-21	5268-5276	clinical	_
39-22	5277-5281	data	_
39-23	5282-5283	.	_

40-1	5284-5287	The	_
40-2	5288-5297	numerical	_
40-3	5298-5309	demographic	_
40-4	5310-5314	data	_
40-5	5315-5318	and	_
40-6	5319-5334	characteristics	_
40-7	5335-5337	of	_
40-8	5338-5351	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
40-9	5352-5355	and	_
40-10	5356-5363	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
40-11	5364-5372	subjects	_
40-12	5373-5377	were	_
40-13	5378-5386	compared	_
40-14	5387-5391	with	_
40-15	5392-5403	independent	_
40-16	5404-5411	samples	_
40-17	5412-5419	t-tests	_
40-18	5420-5421	,	_
40-19	5422-5425	and	_
40-20	5426-5437	categorical	_
40-21	5438-5453	characteristics	_
40-22	5454-5458	were	_
40-23	5459-5467	compared	_
40-24	5468-5473	using	_
40-25	5474-5477	the	_
40-26	5478-5488	Chi-square	_
40-27	5489-5493	test	_
40-28	5494-5495	.	_

41-1	5496-5507	Statistical	_
41-2	5508-5517	threshold	_
41-3	5518-5524	values	_
41-4	5525-5527	of	_
41-5	5528-5529	p	_
41-6	5530-5531	<	_
41-7	5532-5536	0.05	_
41-8	5537-5541	were	_
41-9	5542-5552	considered	_
41-10	5553-5554	a	_
41-11	5555-5566	significant	_
41-12	5567-5577	difference	_
41-13	5578-5579	.	_

42-1	5580-5583	For	_
42-2	5584-5591	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
42-3	5592-5597	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
42-4	5598-5602	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
42-5	5603-5607	data	_
42-6	5608-5616	analysis	_
42-7	5617-5618	,	_
42-8	5619-5621	we	_
42-9	5622-5626	used	_
42-10	5627-5630	FSL	_
42-11	5631-5638	version	_
42-12	5639-5643	5.01	_
42-13	5644-5652	software	_
42-14	5653-5654	(	_
42-15	5655-5673	www.fmrib.ox.ac.uk	_
42-16	5674-5675	)	_
42-17	5676-5677	.	_

43-1	5678-5685	Firstly	_
43-2	5686-5687	,	_
43-3	5688-5696	standard	_
43-4	5697-5710	preprocessing	_
43-5	5711-5716	steps	_
43-6	5717-5721	were	_
43-7	5722-5730	followed	_
43-8	5731-5734	for	_
43-9	5735-5745	individual	_
43-10	5746-5750	data	_
43-11	5751-5752	.	_

44-1	5753-5757	This	_
44-2	5758-5762	step	_
44-3	5763-5771	includes	_
44-4	5772-5779	removal	_
44-5	5780-5782	of	_
44-6	5783-5786	the	_
44-7	5787-5792	first	_
44-8	5793-5794	5	_
44-9	5795-5800	brain	_
44-10	5801-5808	volumes	_
44-11	5809-5810	,	_
44-12	5811-5820	high-pass	_
44-13	5821-5829	temporal	_
44-14	5830-5839	filtering	_
44-15	5840-5841	(	_
44-16	5842-5845	100	_
44-17	5846-5847	s	_
44-18	5848-5849	)	_
44-19	5850-5851	,	_
44-20	5852-5858	motion	_
44-21	5859-5869	correction	_
44-22	5870-5871	,	_
44-23	5872-5877	slice	_
44-24	5878-5884	timing	_
44-25	5885-5886	,	_
44-26	5887-5903	brain-extraction	_
44-27	5904-5907	and	_
44-28	5908-5915	spatial	_
44-29	5916-5925	smoothing	_
44-30	5926-5927	(	_
44-31	5928-5929	5	_
44-32	5930-5932	mm	_
44-33	5933-5937	full	_
44-34	5938-5943	width	_
44-35	5944-5946	at	_
44-36	5947-5959	half-maximum	_
44-37	5960-5968	Gaussian	_
44-38	5969-5975	kernel	_
44-39	5976-5977	)	_
44-40	5978-5979	.	_

45-1	5980-5984	Each	_
45-2	5985-5989	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
45-3	5990-5996	volume	_
45-4	5997-6000	was	_
45-5	6001-6011	registered	_
45-6	6012-6014	on	_
45-7	6015-6025	individual	_
45-8	6026-6036	structural	_
45-9	6037-6042	scans	_
45-10	6043-6046	and	_
45-11	6047-6049	on	_
45-12	6050-6053	the	_
45-13	6054-6062	Montreal	_
45-14	6063-6071	Regional	_
45-15	6072-6081	Institute	_
45-16	6082-6083	(	_
45-17	6084-6090	MNI152	_
45-18	6091-6092	)	_
45-19	6093-6101	template	_
45-20	6102-6107	using	_
45-21	6108-6111	the	_
45-22	6112-6117	FMRIB	_
45-23	6118-6124	Linear	_
45-24	6125-6130	Image	_
45-25	6131-6143	Registration	_
45-26	6144-6148	Tool	_
45-27	6149-6150	(	_
45-28	6151-6156	FLIRT	_
45-29	6157-6158	)	_
45-30	6159-6160	.	_

46-1	6161-6168	Finally	_
46-2	6169-6170	,	_
46-3	6171-6174	the	_
46-4	6175-6185	registered	_
46-5	6186-6190	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
46-6	6191-6200	sequences	_
46-7	6201-6205	were	_
46-8	6206-6216	temporally	_
46-9	6217-6229	concatenated	_
46-10	6230-6234	into	_
46-11	6235-6236	a	_
46-12	6237-6243	single	_
46-13	6244-6260	four-dimensional	_
46-14	6261-6268	dataset	_
46-15	6269-6270	.	_

47-1	6271-6274	The	_
47-2	6275-6279	data	_
47-3	6280-6283	set	_
47-4	6284-6287	was	_
47-5	6288-6298	decomposed	_
47-6	6299-6303	into	_
47-7	6304-6315	independent	_
47-8	6316-6326	components	_
47-9	6327-6328	,	_
47-10	6329-6333	with	_
47-11	6334-6335	a	_
47-12	6336-6340	free	_
47-13	6341-6351	estimation	_
47-14	6352-6355	for	_
47-15	6356-6359	the	_
47-16	6360-6366	number	_
47-17	6367-6369	of	_
47-18	6370-6380	components	_
47-19	6381-6382	.	_

48-1	6383-6385	We	_
48-2	6386-6394	selected	_
48-3	6395-6405	components	_
48-4	6406-6408	of	_
48-5	6409-6417	interest	_
48-6	6418-6420	by	_
48-7	6421-6427	visual	_
48-8	6428-6438	inspection	_
48-9	6439-6444	based	_
48-10	6445-6447	on	_
48-11	6448-6456	previous	_
48-12	6457-6467	literature	_
48-13	6468-6471	and	_
48-14	6472-6475	the	_
48-15	6476-6485	frequency	_
48-16	6486-6493	spectra	_
48-17	6494-6496	of	_
48-18	6497-6500	the	_
48-19	6501-6505	time	_
48-20	6506-6513	courses	_
48-21	6514-6516	of	_
48-22	6517-6520	the	_
48-23	6521-6531	components	_
48-24	6532-6533	.	_

49-1	6534-6539	After	_
49-2	6540-6545	these	_
49-3	6546-6559	preprocessing	_
49-4	6560-6565	steps	_
49-5	6566-6567	,	_
49-6	6568-6572	dual	_
49-7	6573-6583	regression	_
49-8	6584-6592	analysis	_
49-9	6593-6596	was	_
49-10	6597-6606	performed	_
49-11	6607-6610	for	_
49-12	6611-6612	a	_
49-13	6613-6623	voxel-wise	_
49-14	6624-6634	comparison	_
49-15	6635-6637	of	_
49-16	6638-6641	the	_
49-17	6642-6649	resting	_
49-18	6650-6660	functional	_
49-19	6661-6673	connectivity	_
49-20	6674-6677	for	_
49-21	6678-6691	between-group	_
49-22	6692-6700	analysis	_
49-23	6701-6702	.	_

50-1	6703-6710	Spatial	_
50-2	6711-6715	maps	_
50-3	6716-6718	of	_
50-4	6719-6722	the	_
50-5	6723-6728	group	_
50-6	6729-6740	independent	_
50-7	6741-6750	component	_
50-8	6751-6759	analysis	_
50-9	6760-6761	(	_
50-10	6762-6765	ICA	_
50-11	6766-6767	)	_
50-12	6768-6772	were	_
50-13	6773-6777	used	_
50-14	6778-6780	in	_
50-15	6781-6788	general	_
50-16	6789-6795	linear	_
50-17	6796-6801	model	_
50-18	6802-6804	to	_
50-19	6805-6813	generate	_
50-20	6814-6830	subject-specific	_
50-21	6831-6839	versions	_
50-22	6840-6842	of	_
50-23	6843-6846	the	_
50-24	6847-6854	spatial	_
50-25	6855-6859	maps	_
50-26	6860-6861	,	_
50-27	6862-6865	and	_
50-28	6866-6876	associated	_
50-29	6877-6888	time-series	_
50-30	6889-6890	,	_
50-31	6891-6896	using	_
50-32	6897-6901	dual	_
50-33	6902-6912	regression	_
50-34	6913-6917	into	_
50-35	6918-6921	the	_
50-36	6922-6929	subject	_
50-37	6930-6931	’	_
50-38	6932-6933	s	_
50-39	6934-6936	4D	_
50-40	6937-6944	dataset	_
50-41	6945-6946	.	_

51-1	6947-6957	Thereafter	_
51-2	6958-6959	,	_
51-3	6960-6967	spatial	_
51-4	6968-6972	maps	_
51-5	6973-6975	of	_
51-6	6976-6979	all	_
51-7	6980-6988	subjects	_
51-8	6989-6993	were	_
51-9	6994-7003	collected	_
51-10	7004-7008	into	_
51-11	7009-7015	single	_
51-12	7016-7029	4-dimensional	_
51-13	7030-7035	files	_
51-14	7036-7039	for	_
51-15	7040-7044	each	_
51-16	7045-7053	original	_
51-17	7054-7065	independent	_
51-18	7066-7075	component	_
51-19	7076-7077	.	_

52-1	7078-7082	Then	_
52-2	7083-7085	we	_
52-3	7086-7095	performed	_
52-4	7096-7106	voxel-wise	_
52-5	7107-7112	group	_
52-6	7113-7123	difference	_
52-7	7124-7132	analyses	_
52-8	7133-7140	between	_
52-9	7141-7149	subjects	_
52-10	7150-7153	and	_
52-11	7154-7162	controls	_
52-12	7163-7168	using	_
52-13	7169-7182	nonparametric	_
52-14	7183-7194	permutation	_
52-15	7195-7202	testing	_
52-16	7203-7207	with	_
52-17	7208-7214	10,000	_
52-18	7215-7227	permutations	_
52-19	7228-7229	.	_

53-1	7230-7237	Finally	_
53-2	7238-7239	,	_
53-3	7240-7243	for	_
53-4	7244-7252	multiple	_
53-5	7253-7264	comparisons	_
53-6	7265-7266	,	_
53-7	7267-7269	we	_
53-8	7270-7279	conducted	_
53-9	7280-7281	a	_
53-10	7282-7293	family-wise	_
53-11	7294-7299	error	_
53-12	7300-7301	(	_
53-13	7302-7305	FWE	_
53-14	7306-7307	)	_
53-15	7308-7318	correction	_
53-16	7319-7323	with	_
53-17	7324-7325	a	_
53-18	7326-7338	significance	_
53-19	7339-7348	threshold	_
53-20	7349-7351	of	_
53-21	7352-7353	p	_
53-22	7354-7355	<	_
53-23	7356-7360	0.05	_
53-24	7361-7362	.	_

54-1	7363-7365	We	_
54-2	7366-7370	used	_
54-3	7371-7374	the	_
54-4	7375-7389	Harvard–Oxford	_
54-5	7390-7398	cortical	_
54-6	7399-7402	and	_
54-7	7403-7414	subcortical	_
54-8	7415-7422	atlases	_
54-9	7423-7424	(	_
54-10	7425-7432	Harvard	_
54-11	7433-7439	Centre	_
54-12	7440-7443	for	_
54-13	7444-7456	Morphometric	_
54-14	7457-7465	Analysis	_
54-15	7466-7467	)	_
54-16	7468-7470	to	_
54-17	7471-7479	identify	_
54-18	7480-7490	anatomical	_
54-19	7491-7506	representations	_
54-20	7507-7509	of	_
54-21	7510-7518	clusters	_
54-22	7519-7521	of	_
54-23	7522-7525	the	_
54-24	7526-7535	resulting	_
54-25	7536-7549	probabilistic	_
54-26	7550-7561	independent	_
54-27	7562-7571	component	_
54-28	7572-7580	analysis	_
54-29	7581-7585	maps	_
54-30	7586-7587	,	_
54-31	7588-7593	which	_
54-32	7594-7603	indicated	_
54-33	7604-7615	significant	_
54-34	7616-7627	differences	_
54-35	7628-7635	between	_
54-36	7636-7639	the	_
54-37	7640-7643	two	_
54-38	7644-7650	groups	_
54-39	7651-7652	.	_

55-1	7653-7656	The	_
55-2	7657-7668	correlation	_
55-3	7669-7676	between	_
55-4	7677-7685	clinical	_
55-5	7686-7694	symptoms	_
55-6	7695-7698	and	_
55-7	7699-7709	occupation	_
55-8	7710-7716	status	_
55-9	7717-7721	with	_
55-10	7722-7737	between-network	_
55-11	7738-7745	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
55-12	7746-7751	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
55-13	7752-7762	functional	_
55-14	7763-7775	connectivity	_
55-15	7776-7780	were	_
55-16	7781-7785	also	_
55-17	7786-7794	assessed	_
55-18	7795-7800	using	_
55-19	7801-7808	partial	_
55-20	7809-7820	correlation	_
55-21	7821-7822	.	_

56-1	7823-7826	The	_
56-2	7827-7838	statistical	_
56-3	7839-7851	significance	_
56-4	7852-7861	threshold	_
56-5	7862-7865	was	_
56-6	7866-7869	set	_
56-7	7870-7872	at	_
56-8	7873-7874	p	_
56-9	7875-7876	<	_
56-10	7877-7881	0.05	_
56-11	7882-7883	,	_
56-12	7884-7887	FWE	_
56-13	7888-7897	corrected	_
56-14	7898-7899	.	_

